Clinical Trial Update: Dasatinib and Quercetin to Treat Fibrotic Non-alcoholic Fatty Liver Disease [Phase 1, Phase 2]

View source ↗

Summary

A completed Phase 1/2 clinical trial evaluated the combination of dasatinib and quercetin for fibrotic non-alcoholic fatty liver disease (NAFLD/NASH with fibros…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Liver Fibrosis
• Nonalcoholic Fatty Liver Disease
• Nonalcoholic Steatohepatitis with Fibrosis

Drugs mentioned

• DASATINIB (Dasatinib)
• Quercetin (quercetin)

Snippet

Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | Conditions: NAFLD, NASH With Fibrosis | Phase 1, Phase 2 | Status: COMPLETED